Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

212 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer.
Casadevall D, Hernández-Prat A, García-Alonso S, Arpí-Llucià O, Menéndez S, Qin M, Guardia C, Morancho B, Sánchez-Martín FJ, Zazo S, Gavilán E, Sabbaghi MA, Eroles P, Cejalvo JM, Lluch A, Rojo F, Pandiella A, Rovira A, Albanell J. Casadevall D, et al. Among authors: menendez s. Mol Cancer Res. 2022 Jul 6;20(7):1108-1121. doi: 10.1158/1541-7786.MCR-21-0545. Mol Cancer Res. 2022. PMID: 35348729
Mitogen-activated protein kinase phosphatase-1 in human breast cancer independently predicts prognosis and is repressed by doxorubicin.
Rojo F, González-Navarrete I, Bragado R, Dalmases A, Menéndez S, Cortes-Sempere M, Suárez C, Oliva C, Servitja S, Rodriguez-Fanjul V, Sánchez-Pérez I, Campas C, Corominas JM, Tusquets I, Bellosillo B, Serrano S, Perona R, Rovira A, Albanell J. Rojo F, et al. Among authors: menendez s. Clin Cancer Res. 2009 May 15;15(10):3530-9. doi: 10.1158/1078-0432.CCR-08-2070. Epub 2009 May 5. Clin Cancer Res. 2009. PMID: 19417026
MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines.
Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E, Hirsch FR, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J. Arriola E, et al. Among authors: menendez s. Br J Cancer. 2011 Sep 6;105(6):814-23. doi: 10.1038/bjc.2011.298. Epub 2011 Aug 16. Br J Cancer. 2011. PMID: 21847116 Free PMC article.
Nuclear PARP-1 protein overexpression is associated with poor overall survival in early breast cancer.
Rojo F, García-Parra J, Zazo S, Tusquets I, Ferrer-Lozano J, Menendez S, Eroles P, Chamizo C, Servitja S, Ramírez-Merino N, Lobo F, Bellosillo B, Corominas JM, Yelamos J, Serrano S, Lluch A, Rovira A, Albanell J. Rojo F, et al. Among authors: menendez s. Ann Oncol. 2012 May;23(5):1156-1164. doi: 10.1093/annonc/mdr361. Epub 2011 Sep 9. Ann Oncol. 2012. PMID: 21908496 Free article.
Targeting epithelial-to-mesenchymal transition with Met inhibitors reverts chemoresistance in small cell lung cancer.
Cañadas I, Rojo F, Taus Á, Arpí O, Arumí-Uría M, Pijuan L, Menéndez S, Zazo S, Dómine M, Salido M, Mojal S, García de Herreros A, Rovira A, Albanell J, Arriola E. Cañadas I, et al. Among authors: menendez s. Clin Cancer Res. 2014 Feb 15;20(4):938-50. doi: 10.1158/1078-0432.CCR-13-1330. Epub 2013 Nov 27. Clin Cancer Res. 2014. PMID: 24284055
Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-кB target genes in human breast cancer.
Dalmases A, González I, Menendez S, Arpí O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincón R, Espinosa L, Bigas A, Eroles P, Furriol J, Lluch A, Rovira A, Albanell J, Rojo F. Dalmases A, et al. Among authors: menendez s. Oncotarget. 2014 Jan 15;5(1):196-210. doi: 10.18632/oncotarget.1556. Oncotarget. 2014. PMID: 24344116 Free PMC article.
Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway.
Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, Arpi O, Corominas JM, Bragado R, Servitja S, Tusquets I, Nonell L, Macià F, Martínez J, Rovira A, Albanell J, Castells X. Rojo F, et al. Among authors: menendez s. Cancer Epidemiol Biomarkers Prev. 2014 Feb;23(2):288-99. doi: 10.1158/1055-9965.EPI-13-0761. Epub 2013 Dec 17. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24347552
High circulating hepatocyte growth factor levels associate with epithelial to mesenchymal transition and poor outcome in small cell lung cancer patients.
Cañadas I, Taus A, González I, Villanueva X, Gimeno J, Pijuan L, Dómine M, Sánchez-Font A, Vollmer I, Menéndez S, Arpí O, Mojal S, Rojo F, Rovira A, Albanell J, Arriola E. Cañadas I, et al. Among authors: menendez s. Oncotarget. 2014 Jul 30;5(14):5246-56. doi: 10.18632/oncotarget.2124. Oncotarget. 2014. PMID: 25026301 Free PMC article.
Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J. García-Parra J, et al. Among authors: menendez s. Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12. Eur J Cancer. 2014. PMID: 25128455
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects.
Rincón R, Cristóbal I, Zazo S, Arpí O, Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, García-Foncillas J, Madoz-Gúrpide J, Rojo F. Rincón R, et al. Among authors: menendez s. Oncotarget. 2015 Feb 28;6(6):4299-314. doi: 10.18632/oncotarget.3012. Oncotarget. 2015. PMID: 25726524 Free PMC article.
212 results